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Abstract 
Systemic lupus erythematosus (SLE) is a chronic and systemic autoimmune disease characterized by 
auto-antibody production, immune complex deposition and multi-organ involvement. Although the 
etiology of SLE is believed to be influenced by multiple aspects, such as genetic, epigenetic, 
environmental, hormonal, and immunoregulatory factors, the pathogenesis of SLE is not completely 
understood yet. B cells play a central role in the development of SLE. IL-10 acts as a growth factor 
for B lymphocytes. It can promote B cell survival, improve proliferation and differentiation to 
plasmablasts, and increase antibody production. Many studies have demonstrated that IL-10 
expression levels are increased in the serum of SLE patients and peripheral blood mononuclear cells 
(PBMC) from SLE cases in the worldwide. To date, the underlying mechanism remains unclear. To 
fully explain the upregulated IL-10 expression in SLE patients, it is first time for us to put attention 
on its posttranscriptional regulation in SLE. Therefore, we mainly focused on the difference of 
degradation rates of IL10 mRNA in SLE versus controls and its underlying mechanism in this study. 
Firstly, we established a reliable condition to detect human IL-10 transcripts without cross-reaction 
with the EBV-derived viral IL-10 in lymphoblastoid cell lines (LCLs). We then measured IL-10 
mRNA degradation rates 25 human LCLs from SLE and control all who are from European 
Americans. It is surprise to find that faster IL-10 mRNA degradation rate in SLE. We hypothesized 
that Tristetraprolin (TTP), a RNA binding protein might play a role in IL-10 mRNA degradation. 
Thus, we measured its expression level and found decreased TTP protein expression levels in SLE 
compared to controls. Meanwhile, we identified a weak correlation between IL-10 mRNA and TTP 
mRNA, and observed a trans-effect of IL-10 potential causal variants on TTP mRNA expression 
levels in SLE. Collectively, our work not only demonstrates the degradation rate of IL-10 mRNA in 
 II 
LCLs from SLE and controls, but also uncovers the previously understudied mechanism of the 
correlation between TTP mRNA and IL-10 mRNA and of trans-effect of IL-10 genotype on TTP 
mRNA expression in SLE. This study provides a new potential mechanism for pathogenesis and 
opening a window for a new approach to clinical treatment. 
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Chapter 1. Background and design of primers 
specific to human IL10 and BCRF1 
 
1. Introduction 
1.1 Systemic lupus erythematosus  
Systemic lupus erythematosus (SLE) is a chronic and systemic autoimmune disease 
characterized by auto-antibody production, immune complex deposition and multi-organ 
involvement [1]. Its prevalence is from 20 to 150 cases per 100,000 in the population, with 
gender imbalance, typically occurring in women of childbearing age [1]. The course of SLE 
is unpredictable, with flares alternating with remissions. It can be fatal when the brain, 
blood and kidney are attacked. Although the etiology of SLE is believed to be influenced by 
multiple aspects, such as genetic, epigenetic, environmental, hormonal, and 
immunoregulatory factors, the core part for development of effective therapeutics is to 
decrease the production of a variety of autoantibodies in terms of immunopathology [2].  
 
1.2 Role of B lymphocytes in SLE  
B cells play a central role in the pathogenesis of SLE [3, 4]. The pathogenic significance is 
supported by the prominent production of various autoantibodies that can bind to autoantigens in the body. 
For example, positive antinuclear antibodies are observed in 98% of SLE patients [5]. Specifically, 
anti-Smith antibody is a very specific marker for diagnosis of SLE, and anti-double stranded DNA 
antibodies are highly associated with SLE activity [6, 7]. Additionally, it has been observed that certain 
SLE-specific autoantibodies tend to fluctuate with SLE activity [6, 8-10]. These observations collectively 
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suggest that B cells mediated by the ongoing immune response are the main source of production of 
autoantibodies that affect the disease.  
 
1.3 Immunological activity of Interleukin-10  
1.3.1 Immunosuppressive function  
Interleukin-10 (IL-10) is an important immunoregulatory cytokine with ubiquitous 
sources such as T lymphocytes, B lymphocytes, monocytes, macrophages, dendritic cells 
(DCs), etc. IL-10 receptors are fairly prevalent among both immune and non-immune cells, 
granting its ability to elicit a wide range of responses. IL-10 acts through its receptors, 
activates and phosphorylates Janus kinase 1, tyrosine kinase 2 and STAT3, then activates 
STAT3 transfer into the nucleus, inducing transcription of the corresponding anti-apoptotic 
and cell-cycle-progression genes such as BCLXL, Cyclin-D1, Cyclin-D2, and Cyclin-D3 
[11, 12]. IL-10 works as an anti-inflammatory factor on macrophages, Th1 cells, and 
dendritic cells, inhibiting the expression of major histocompatibility complex class (MHC II) 
genes, decreasing the expression of co-stimulatory molecules CD80 and CD86 [13], 
suppressing production of IL-1, IL-6, IL-8, tumor necrosis factor-α(TNF-α), etc. [14]. 
IL-10 can also inhibit DCs differentiation and maturation from monocyte precursors [15, 
16]. Through these and other mechanisms, IL-10 production limits a prolonged 
inflammatory episode triggered by infection. 
 
1.3.2 Immunostimulatory function 
However, not all effects of IL-10 are immunosuppressive. IL-10 can also work as an 
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immune- stimulatory player that can improve natural killer cells activation, CD8 T cell 
proliferation and regulatory T cell functions [13, 17, 18]. IL-10 is also a growth factor for B 
lymphocytes. It can promote B cell survival, improve proliferation and differentiation to 
plasma B cells, increase antibody production, and upregulate MHC class II expression [17]. 
Thereby, IL-10 is a critical cytokine for understanding the elevated levels of autoantibodies 
from B cells in lupus patients generated by the ongoing immune response.    
 
1.4 IL-10 dysregulation in SLE 
Many studies have demonstrated that IL-10 expression levels are increased in the serum 
of SLE patients and peripheral blood mononuclear cells (PBMC) from SLE cases [18-33]. 
Further, studies also have shown that IL-10 levels are positively associated with disease 
activity [18, 21-24, 26, 27]. In general, B lymphoblasts and myeloid cells are the main 
producers of IL-10 transcripts among immune cells, as shown in Figure 1. As early as 1993, 
Llorente L et al. observed that B cells and monocytes contribute a considerable amount of 
IL-10 in PBMCs from SLE [32].  It is thought that B cell-derived IL-10 can act in a 
paracrine and autocrine manner to maintain autoantibody production in B cells from SLE. A 
recent study from Betty Tsao’s group also found an increased presence of IL-10+p-Elk-1+ 
(phosphorylated ETS like transcription factor 1) in B cells from SLE in European American 
patients [31].  Their work further suggests that preferential binding of Elk-1 to a 
SLE-associated IL10 risk allele is highly associated with higher expression of IL-10 in SLE.  
Interestingly, these seemingly promising observations have become controversial 
because of three studies reporting no significant difference of IL-10 expression level 
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between SLE and healthy controls [34-36]. This is not surprising, since sample size, patients 
with different ancestry, clinical symptoms, or secretion of viral IL-10 (a related molecule 
produced by Epstein-Barr virus) could have major impacts on these results. Thus, despite a 
clear relevance of IL-10 to SLE, much remains to be understood about its regulation.   
 
1.5 Role of Epstein-Barr virus in SLE 
Epstein-Barr virus (EBV), also known as human herpes virus (HHV4), is carried by 
approximately 95% of the population in the world [37]. 99.5% of adult SLE patients are 
EBV infected [37], suggesting that EBV infection might play a role in the etiology of SLE. 
Further, 40-fold increased viral load was found in the PBMCs from SLE cases [38]. 10-fold 
increased frequency of EBV-infected B cells was observed in the peripheral blood in SLE. 
Taken together, these highlight that SLE patients are less capable of controlling EBV lytic 
cycle with prominent virus replication [38, 39]. Poole et al. examined EBV genes 
expression in PBMCs from SLE and found a 1.7 fold-increase in Epstein–Barr virus nuclear 
antigen-1 (EBNA-1, a protein which has Glycine-Alanine repeats that seem to impair  
peptide processing and MHC class I-restricted antigen presentation, similar to certain 
SLE-specific autoantigens) [38, 40-42]. This immunologic similarity between EBV proteins 
with key SLE-specific autoantigens highly suggests that a molecular mimicry mechanism 
may partially explain the autoantibody development in SLE [6, 43-46]. Animal models have 
also demonstrated that immunization of mice with the cross-reactive EBNA-1 peptides led 
to the production of anti-Smith antibody, anti-Ro antibody, anti-double strand DNA 
antibody and other lupus-like symptoms [47].   
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1.6 EBV derived viral IL-10 
The EBV BCRF1 gene encodes a protein, known as viral IL-10, which shares 78.8% 
amino acid sequence identity with human IL-10 (Figure 2) [48]. BCRF1 shares highest 
cross-homology with human IL10 at its exon2, exon4 and exon5 regions, which might be 
misrecognized for human IL10 (Figure 2). Of interest, this is one of many strategies used by 
EBV to successfully disrupt host antiviral immune response and become undetectable by the 
host immune system [49]. Functional studies illustrated that viral IL-10 preserves 
immunosuppressive activity, like human IL-10, inhibiting MHC class II expression on 
monocytes, limiting interferon γproduction, and deactivation of macrophages [50-55]. 
Also, viral IL-10 maintains some immunostimulatory functions such as promotion of B cell 
proliferation and differentiation, and stimulation of antibody production [56-58]. 
 
There are some properties that viral IL-10 does not have due to subtle structural differences from 
human IL-10, such as a 1000-fold-lower binding affinity to the human IL-10 receptors when 
compared to human IL-10, and its incapability of upregulation of MHC class II surface expression on 
B cells [57-60]. Although these dissimilarities are different enough to be distinguished at transcript 
and protein levels, primers and probes of human IL-10 or antibodies used in previous studies might 
have cross-reacted with viral IL-10 (see more in discussion part). Thus, decided major goal of this 
chapter is to design the BCRF1-specific and human IL10-specific primers and probes without cross 
reactivation. 
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2. Goals of this chapter 
Many studies have demonstrated that elevated IL-10 levels had been found in the serum and 
PBMCs from SLE patients. However, increased EBV viral load and upregulated EBV lytic viral 
mRNA in SLE suggest that there is a possibility that viral IL-10 may contribute to the total higher 
IL-10 expression in SLE patients. Thus, it is necessary to establish the conditions that reliably 
distinguish the host and BCRF1 message with no cross reaction. 
The specific aims of this chapter are: 
1. To develop the primers and probes which can only amplify human IL10 mRNA 
2. To design the primers and probe which can only amplify BCRF1gene 
 
3. Materials and methods 
3.1 Human IL-10 producing cells without viral IL-10 contamination 
BJAB cell line is an EBV negative cell line (gift from Dr. William Miller’s lab). It was 
cultured in RPMI 1640 media with 10% (v/v) heat inactivated fetal bovine serum (FBS) 
(Life Technologies) and anti-anti (100X) antibiotic-antimycotic (AAA) (Life Technologies). 
Cells were maintained at a density between 5x10
5
 and 1x10
6
 cells/ml in 37ºC incubator 
with a humid atmosphere of 5% CO2. Half media was changed every two days.  
 
3.2 Viral IL-10 producing cells 
B95-8 is an EBV producing cell line (ATCC). Flow cytometric analysis indicated that 
20-30% EBV-infected B cells are at their lytic status, when they are productive for viral 
replication and producing viral IL-10. It was cultured in RPMI 1640 media with 10% (v/v) 
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heat inactivated fetal bovine serum (FBS) and AAA. Cells were maintained at a density 
between 5x10
5
 and 1x10
6
 cells/ml in 37ºC incubator with a humid atmosphere of 5% CO2. 
Half media was changed every two days.  
 
3.3 Real time quantitative reverse transcription-PCR 
Total RNA was extracted from cell lines using RNeasy mini kit (QIAGEN) and reverse 
transcription PCR reactions were performed and measured on 7500 Real Time PCR System 
(Applied Biosystem) using SuperScript reverse transcriptase (Life Technologies) and 
Taqman gene expression master mix (Life Technologies). Reverse transcriptase was 
performed at 37°C for 1 h, followed by heat inactivation at 95°C for 5min to inactivate the 
enzyme. cDNA was then amplified by primers and probes on 7500 Real Time PCR System. 
BCRF1 primers and probe, human IL10 Primer 1(IL10 probe: Hs00174086_m1) were 
ordered from Life Technologies. Human IL10 primer 2 and primer 3 are designed by 
Primer3 software program and ordered and from IDT (Figure 3). Probes were conjugated to 
FAM dye label on the 5’ end, and minor groove binder nonfluorescent quencher on the 
3’end. The relative expression was calculated using the ΔCt method with the HPRT1 gene 
(Applied Biosystems) as housekeeping gene.  
 Considering BCRF1 primers and probes might amplify viral DNA while measuring 
transcripts expression, we used TURBO DNA-free kit (Applied Biosystems) to remove 
contaminated genomic DNA. Even this procedure can not 100% remove all DNA 
contamination but it can reduce the levels below the detection limits of a standard real-time 
PCR (Figure 4).  
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3.4 Extraction of viral DNA and human genomic DNA 
PureLink viral RNA/DNA kits (invitrogen) were used to extract viral DNA from B95-8 
cell lines. 25ul proteinase K and 200ul lysis buffer containing 5.6ug carrier RNA were 
added into 200ul of supernatant of B 95-8 cell line. Vortex it and incubate it at 56ºC for 15 
minutes. We added 250ul 100% ethanol and incubate the lysate for 5 minutes at room 
temperature. We added the lysate to the viral spin column and centrifuge it at 6800xg for 1 
minute, washed the column with wash buffer and ethanol three times, centrifuged the spin 
column at maximum speed for 1 minute to remove any residual wash buffer, placed the 
column and elute with 30ul sterile RNase-free water, incubated it at room temperature for 1 
minute, and centrifuged the column at maximum speed for 1 minute to elute nucleic acids. 
Then, we stored purified DNA and measured its concentration by Nanodrop ND-1000 
spectrophotometer.  
 
3.5 Agarose gel electrophoresis 
DNA fragments or q RT-PCR products were separated via (2%) agarose gel 
electrophoresis. The gels were prepared by dissolving the agarose in the TAE buffer. To 
visualize the DNA, 5 µl of (10 mg/ml) ethidium bromide was added to the 60 ml (2%) 
agarose solution. To load the samples, the DNA was mixed in equal volume ratios with the 
agarose gel loading buffer. Electrophoresis was performed at 190 V. The DNA was detected 
using UV light and the size of the DNA was determined using standard 1Kb DNA ladder. 
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4. Results      
4.1 BCRF1 primers and probe can distinguish between viral DNA and human cDNA 
To measure BCRF1 and human IL10, it is necessary to establish a situation that reliably 
distinguishes host and BCRF1 transcripts with no cross reactivity. To test the BCRF1 
primers and probe, we used B95.8 cell lines or viral DNA as positive controls, and BJAB 
cell lines (which is an EBV negative cell line) as negative controls. A previous study found 
30-fold increased IL10 level in BJAB cell lines after CpG ODN type B (CpGB) treatment 
6h [56]. Thus, we also tried to detect BCRF1 amplification in BJAB cell lines after CpGB 
treatment at 6h, 12h, and 24h. We observed that BCRF1 primers and probe cannot amplify 
human IL10 cDNA either at its low level or high level in BJAB cell lines (Figure 4A and B). 
BCRF1 primers and probe also can amplify BCRF1 in B95.8 cell line or viral DNA (Figure 
4A and B). However, BCRF1 DNA might be a contaminant, since BCRF1 lacks of exons 
and introns that means reverse transcription products are mixture of DNA and mRNA. We 
cannot guarantee that there is no DNA contamination in mRNA samples. To solve this 
problem, a standard curve was generated using 0.5ng, 5ng, and 50ng viral DNA. Meanwhile, 
its cross-reactivity with human genomic DNA (gDNA, extracted from EBV-transformed 
human B cell line) was tested. As we expected, BCRF1 primers and probe can amplify viral 
DNA. Of interest, as growing concentration of human gDNA, the cross-reactivity between 
BCRF1 and human gDNA increased to as high as 3-4% (Figure 4C). This observation 
suggests the essentiality of removing human gDNA contamination in mRNA samples for 
BCRF1 transcript detection. Using TURBO DNA-free kit, we reduced gDNA 
contamination level below the detection limits of real-time PCR (Figure 4D). 
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Taken together, our data provide evidence supporting that the BCRF1 primers and 
probe we designed can reliably distinguish host IL10 cDNA and viral DNA. Also, they can 
be used to effectively measure BCRF1 transcripts in DNase-treated mRNA samples. 
   
4.2 Human IL10 primers and probe can distinguish host and BCRF1 mRNA  
To test our human IL10 primers and probes, we used one pair, named primer 1, which 
was ordered from Life Technologies as our positive control for total IL10 transcripts 
detection. Since its detailed sequence information is not available, thus it is unsure whether 
it could have cross-reactivity with BCRF1.  
Meanwhile, we designed our own probes by aligning BCRF1 and human IL10 mRNA 
as shown in Figure 2, avoiding regions of cross-homology, and designing another two pairs 
named primer 2 (spanning an exon 3-exon 4 junction) and primer 3 (located in the exon 5 of 
3’ end). Note that primer 3 potentially might bind to residual genomic DNA since its primer 
location is not spanning an exon junction. It is used as one of our alternatives in case other 
pairs do not work.    
As shown in Figure 5A, primer 2 gave higher PCR efficiencies than primers 1 and 3, 
either at low or high levels of human IL10 expression in BJAB cell line. This result was 
confirmed by agarose gel electrophoresis (Figure 5B). We found that each lane either from 
primer 1, primer 2 or HPRT1 has only one band in the CpGB treatment 6 hours group, but 
no bands in minus reverse transcript (RT-) group where no addition of reverse transcriptase. 
RT- group acting as our negative control is to test genomic DNA contamination in RNA 
samples. The absence of bands suggests no cross-reactivity between primers and genomic 
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DNA.  To further establish that the BJAB cell line is an EBV negative cell line, BCRF1 
also was detected at the same time, with no observed amplification.  
The last concern for us was whether primer 2 might amplify the BCRF1 mRNA. We 
used primer1 and primer 2 to detect and amplify the IL10 gene in viral DNA that we 
extracted from the B95.8 cell culture supernatant with positive control— BCRF1 primer and 
probe. As we see in Figure 5C, no amplification was found in viral DNA, which suggests 
that primer 1 and primer 2 cannot detect or amplify the BCRF1 transcripts.  
 
5. Discussion 
To date, B-cell-depleting antibody treatments for SLE have not provided satisfactory results [3]. 
The current strategy has moved to focus on the agents that modulate B cell growth and 
differentiation [3]. IL-10 has proliferative impact on autoantibody producing B cells, which are 
believed to be one of the potential therapeutic targets for SLE. In past decades, an increasing number 
of studies have demonstrated enhanced IL-10 expression in SLE patients when compared to healthy 
controls, both in vivo and vitro. In our study, we mainly focus on human IL10 mRNA stability and 
its underlying mechanism in SLE. Considering the potential influence from BCRF1 on human IL10 
transcripts detection, we decided to establish a condition that can detect human IL10 transcripts 
without cross activity with BCRF1 in this chapter, in order to exclude the impact of BCRF1 on our 
studies. 
As mentioned above, we generated one BCRF1 pair which has been confirmed by the negative 
control of EBV-negative BJAB cell line and the positive control of EBV-producing B95.8 cell lines. 
It helped us to assess the specificity of human IL10 pairs and also can be used to measure BCRF1 
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transcripts in future studies.  
For the human IL10 primers and probe, it is essential to design ones that do not cross react with 
BCRF1 transcripts. To filter out the best human IL10 primers and probe, we examined ones used in 
many studies, such as IL10 Hs00961622， from Life Technologies [25]. It spans the exon4 and 
exon5 boundaries, which have the highest cross-homology region with BCRF1 (Figure 2). In a study 
by E. Pocsik et al., their IL10 primers whose amplicon has 269bp and spans exon1 and exon 2, 
highly match with BCRF1 [57]. These highly matched regions are not different enough to distinguish 
BCRF1 and human IL10. Thus, it is quite likely that previous studies of human IL10 have been 
confounded by BCRF1. 
In our study, we followed the primers and probe design principles like: the amplicons length of 
70-150 bp is most easily amplified under standard cycling conditions; it is best to design primers and 
probe towards the 3’end of IL10 since the reverse transcription reaction started transcription within 
500-1000 bases from the poly A site; two base pair differences at 3’end of primers and probe are 
distinct enough to distinguish different genes. Eventually, we established two pairs of primers and 
probe named Primer2 and Primer 3. Primer 1 ordered from Life technologies worked as a control. 
Primer 2 spans exon3 and exon4 junction which can be used to detect human IL10 mRNA directly 
without cross reactivity with BCRF1. Primer 3 in exon5 and 3’end of IL10 region where no 
homology regions shared with BCRF1, but its weakness is its potential amplification of gDNA. Thus, 
it requires DNase treatment before quantification if using Primer 3 to detect human IL10 
amplification. Meanwhile, we also compared primer 1 with primer 2, both of which span exon3 and 
exon4 junction, and found that primer 2 is more efficient than primer 3 to quantitate transcripts.  
Taken together, Primer 2 can be used to detect human IL10 transcripts in our EBV-transformed 
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B cell lines, without cross reactivity with viral IL-10. This finding builds a strong foundation for our 
next steps to detect the degradation rate of human IL10, and explore the underlying mechanism of 
posttranscriptional regulation in SLE patients.  
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Figure 1 
 
Figure 1. IL10 transcripts expressions in distinct tissues and cell types.  
These data are provided from the BioGPS dataset library. IL10 mRNA is expressed in many tissues, including 
lymph nodes and spleen. Among different cells, CD33+ myeloid cells and B lymphoblasts express relatively higher 
level of IL10 transcripts.  
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Figure 2. 
 
 
 
 
Figure 2. Alignment of sequences of EBV-derived BCRF1 and human IL10 transcript. Identical 
nucleotides are highlighted by asterisks under the human IL10 sequence. EBV-derived BCRF1 is 
632bp long, and its location is from base 9631 to 10262 in the EBV complete genome. Human IL10 
transcript has 1629bp. EBV-derived BCRF1 shares approximately 67.1% identity with human IL10 
transcript. 
 16 
 
Figure 3  
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Figure 3. Primers and probes of BCRF1 and human IL10 used for measuring primary 
transcripts and mature transcripts 
Primers and probe are designed for measuring either BCRF1 message RNA (A) or human IL10 
mRNA (B and C). In this figure, BCRF1 mRNA and human IL10 mRNA sequences were aligned. 
Red rectangle is to indicate the parts where shared sequences are relatively aggregated. Probe 
locations are shown in red, left primers have a grey shadow, right primers are shadowed with bright 
blue, and yellow shadows show the locations where sequences are masked due to repeats. BCRF1 
left primer: left primer (from 5’ end to 3’end): GCGAAGGTTAGTGGTCACTC; probe: 
TGGCACCTGAGTGTGGAGG; right primer’s position: AGAGATGCCTTCAGTCGTGTTAAAA 
C.  Human IL10 primer 2: left primer (from 5’ end to 3’ end): TGAGAACCAAGACCCAGACAT; 
probe: CAAGGCGCATGTGAACTCCCT; right primer’s position: TCATCGATTTCTTCCC 
TGTGAA. Human IL10 primer 3: left primer (from 5’ end to 3’ end): CTTCCATTCC 
AAGCCTGACCA; probe: CGCTTTCTAGCTGTTG; right primer’s position: CTGTTTTCCCTG 
ACCTCCCTC. 
 
 
 
 
 
 
C 
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Figure 4  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Effectiveness and specificity of BCRF1 primers and probe. (A) Viral IL-10 gene 
relative expression over HPRT1 in B95.8 cell line and BJAB cell line in the absence or presence of 
CpGB treatment. BJAB is a negative control and B95.8 cell line is a positive control. (B) 
Expressions of isolated viral DNA and human IL10 cDNA (both quantitative RT-PCR products were 
amplified by BCRF1 primers) were detected by agarose gel electrophoresis. The absent band in 
human IL10 cDNA lane suggests that there is no cross-reactivity between viral DNA and human 
cDNA. Viral DNA was extracted from B95.8 cell culture supernatant. Human cDNA fragment is 
from PCR product in BJAB group without CpGB treatment. (C) To clarify the cross-reactivity 
between BCRF1 primers and genomic DNA (gDNA), absolute quantification plot were generated. 
Standard curve was calculated by using viral gDNA and human IL10 gDNA. R
2
=0.995. We loaded 
gDNA with different concentrations (viral gDNA 0.5ng, 5ng and 500ng; human gDNA 1ng, 10ng 
and 100ng). As we see, viral gDNA were amplified by BCRF1 primers even only 0.5ng gDNA were 
loaded. But the cross-reactivity between viral BCRF1 primers and human gDNA can be detected 
only when human gDNA loading concentration reaches 100ng. (D) To address gDNA contamination, 
we used TURBO DNA-free kit to remove gDNA. The absent band in human gDNA lane indicates 
no BCRF1 amplification in agarose gel electrophoresis.  
HPRT1 
A B 
BCRF1 primers and probe test 
 
 
C D 
A B
b 
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Figure 5 
 
 
 
Figure 5. Effectiveness and specificity of different human IL10 primers and probes. 
(A) Three different pairs of primers and probes were used to detect human IL10 mRNA expression in 
the absence or presence of CpGB treatment. The first pair named primer 1 was ordered from Life 
Technologies as a positive control. The second one (primer 2) and the third one (primer 3) have been 
mentioned above, respectively corresponding to B and C in Figure 3. To detect the contamination of 
genomic DNA, reverse transcription negative (RT-) controls were set up. (B) Agarose gel 
electrophoresis was performed to visually investigate the specificity of primer 1 and primer 2. 
Meanwhile, BCRF1 primers as negative controls were used to detect EBV infection on BJAB cell 
lines. RT- groups acting as negative control as well is for measurement of contamination of human 
gDNA. HPRT1 is our housekeeping gene. (C) To identify the cross-reactivity between human IL10 
primers and viral gDNA, human IL10 amplification has been quantitated by primer 1 and primer 2 in 
viral DNA. BCRF1 amplification acts as positive control. No bands shown in primer 1 and primer 2 
lanes suggest that primer 1 and primer 2 cannot amplify viral gDNA.  
 
 
 
 
A 
 A 
B 
C 
A B 
C 
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Chapter 2 Human IL10 mRNA degradation in SLE 
1. Introduction 
1.1 Steady-state gene expression  
In general, steady-state gene expression is a result of the dynamic interplay between 
transcriptional and post-transcriptional mechanisms [61]. The process of gene expression 
begins with initiation of transcription by specific transcription factors, followed by 
elongation, RNA capping, RNA splicing, 3’ end cleavage, mature RNA selection, nuclear 
export，spatial localization in cytoplasm, and on to the initiation of protein synthesis. Each 
step beyond initiation is controlled by posttranscriptional regulation [62]. Although previous 
studies have shown that some dysregulated genes directly contribute to the pathogenesis of 
a number of diseases and these genes become therapeutic targets used for clinical treatments 
eventually such as Interferon-gamma, not all therapy is effective enough to cure diseases or 
control the progress [63]. One of main reasons is that the richness of post-transcriptional 
mechanism has been relatively understudied.  
With respect to the study of IL-10, to explain the spontaneously upregulated IL-10 
expression in SLE patients, a recent report from Betty Tsao’s group demonstrated that 
preferential binding of Elk-1 to the SLE-associated IL10 risk allele rs3122605 elevates IL10 
expression [31]. However, this risk allele is only associated with SLE susceptibility in 
European Americans (EA), and not in other ancestries where share common regulatory 
effects with EA but 17-29% of loci express significantly different levels in the study on 270 
individuals of the four worldwide HapMap II populations from Northern and western 
European origin, Beijing, Tokyo, and Nigeria [64]. This suggests the possibility that 
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pathogenic posttranscriptional regulation might play a role in the mechanism of 
spontaneously elevated IL-10 expression in SLE patients across ancestries. In this chapter, 
we examine this possibility by focusing on the difference of degradation rates of IL-10 
mRNA in SLE vs controls and its contribution to overall steady-state expression.   
  
1.2 Posttranscriptional regulation  
Posttranscriptional regulation of gene expression occurs on multiple levels (see 
previous section). The focus of our study is on one particular step: mRNA degradation [62].  
 
1.2.1 Pathways of mRNA degradation 
The process of mRNA degradation is an integral part of the posttranscriptional 
regulation system. Fan et al. reported that in stress-inducing agent treated human cell lines, 
approximately 50% of affected transcripts were due to their altered mRNA stability not 
changed yield [65]. mRNAs are regulated in several pathways [66, 67]. Deadenylation of 
poly(A) tails is a common exonucleolytic way for polyadenylated transcripts to decay. Some 
transcripts go through decapping first then get destabilized by the exonuclease Xrn1. Other 
transcripts can degrade after endonucleolytic cleavage [68]. In addition, quality-control 
mechanisms are involved in this step to keep faulty transcript degradation under 
surveillance [69]. Nonsense-mediated decay (NMD) is one of the mechanisms, in which 
transcripts with premature stop codons get decapped and decay from their 5’ends. If faulty 
transcripts are deficient of stop codons, they are destabilized in the exosome [69].  
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1.2.2 The mechanics of mRNA degradation 
Recently, increasing numbers of studies provide critical insights into the mechanics of 
mRNA degradation. Most of them underscore two players: microRNAs and RNA binding 
proteins. MicroRNAs (miRNAs) are small non-coding RNAs that function at the 
posttranscriptional regulation level via silencing sequences that base-paire with miRNA 
within mRNA molecules. Over 1000 miRNAs are encoded in the human genome [70]. 
Many are thought to have disease relevance.  For example, decreased miRNA164 has been 
demonstrated to be highly associated with the development of SLE [71] (more are detailed 
in chapter three).  
RNA-binding proteins (RBP) are proteins, characterized by their structural motifs 
which can specifically recognize their RNA targets through specific binding in order to 
either stabilize or destabilize them in cells. RNA-binding domains utilize domains such as 
the RNA-recognition motif (RRM), double-stranded RNA –binding motif, and zinc-finger 
motifs to recognize short, degenerate RNA sequence and structural “motifs” [72, 73]. For 
instance, if an unstable mRNA carries adenosine and uridine (AU)-rich elements (AREs) in 
its 3’ untranslated region (3’ UTR), it will often become a target for several RBPs [74]. 
AREs are one common motif which varied in different genes due to different sequences or 
different combination of AREs. Pentamers of the sequence AUUUA are repeatedly arranged 
and/or overlapped with each other. This regulatory sequence, one of most common 
determinants of mRNA degradation or stability, has mostly been found in genes encoding 
proto-oncogenes, nuclear transcription factors and cytokines [75]. In particular, IL-10 is one 
of many cytokines containing AREs in its 3’UTR.  
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1.2.3 Role of IL10’s AREs in mRNA degradation 
AREs are common targets for RBPs to destabilize or stabilize ARE-containing genes. 
However, not all AREs play their role in mRNA degradation determinants, such as the 
nuclear transcription factor krox20 and zif268 both of which contains inefficient AREs in 
their 3’UTR [76]. Thus, it is important to assess the role of IL10 AREs in mRNA 
degradation. Srijata Sarkar inserted different regions of the IL10 3’ UTR segments 
downstream of the luciferase open reading frame in plasmid pGL3-Promoter and transfected 
these chimeric constructs into THP-1 cells [77]. They found that when compared to the 
pGL3-Promoter control construct containing luciferase gene, the one containing the entire 
IL10 3’UTR exhibited the fastest mRNA degradation (>90%) in THP-1 cells and the first 
five AUUUA motifs provided high degradation capability (>50%) [77]. Gary Brewer et al 
performed a similar study [78]. They added different regions of IL10 3’ UTR into the 
β-globin gene (which has high mRNA stability) and transfected them into Hela cells. Like 
previous results, IL10 AREs insertion decreased the half-life of β-globin from 13h to 1.5h 
[78]. Both of these studies suggest that IL10’s AREs can confer instability and are mRNA 
degradation determinants.                    
 
1.2.4 Overall degradation rate of human IL10 mRNA  
As mentioned above, multiple factors can affect human IL10 mRNA degradation, such 
as miRNAs, RBPs and AREs. To investigate mRNA degradation, it is common to measure 
degradation rate and half-life of mRNA. Generally, genes with short half-life of mRNA 
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usually exhibit fast mRNA degradation rates. In our study, we calculated degradation rate 
and half-life based on a one-phase degradation one-phase exponential decay equation model 
(see materials and methods).  
To date, it remains unclear about the degradation rate and half-life of IL10 mRNA in B 
cells either from SLE or healthy controls, though studies in different cell types and disease 
statuses have been reported. Gary Brewer observed that the half-life of IL10 mRNA was 
seven minutes in normal melanocytes, but in the melanoma cell line MNT1 it increased to 
75 minutes [78]. Trong Le et al found that the half-life of IL10 mRNA was 60 minutes in 
both adults and term neonate PBMCs [79]. This suggests that each cell type has its own 
particular set of posttranscriptional regulation-machineries. Additionally, external stimuli 
also can alter the stability of mRNA [80]. For instance, ultraviolet light exposure enhanced 
the stability of many short-lived mRNAs in mammalian cells [81]. Thus, it is possible that 
the half-life of IL10 mRNA might be altered under the pathogenic situation of SLE patients.  
Taken together, IL10 mRNA’s half-life in B lymphocytes to some extent might be 
different from that of other cell types. Further, considering that B cells are one of the main 
producers of IL10 in the human body and dysregulated IL10 expression levels in SLE have 
been demonstrated by many studies (see chapter one), we decided to measure the half-life 
and degradation rate of IL10 mRNA in B cells and assess the difference in SLE vs controls.  
  
2. Goals of this chapter 
Posttranscriptional regulation provides a comprehensive view to the knowledge of molecular 
biology, but its role in the steady-state gene expression has been understudied for a long time. In our 
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study, to discover the contribution of posttranscriptional regulation to the pathogenesis of SLE, we 
analyzed the degradation rate and half-life of human IL10 mRNA in EBV-transformed B cells from 
SLE and healthy controls with European ancestry, to exclude the potential influence of ancestry.  
Also, we controlled the impacts of IL10 SNPs on degradation rates through controlling cell lines 
carrying potential causal variants of IL10 gene which are highly associated with SLE risk.  
Our hypothesis is that the degradation rate of human IL10 mRNA in EBV-transformed B cells 
from SLE is slower than that of healthy controls since numerous studies have demonstrated that 
increased IL10 expression have been observed in serum and PBMCs from SLE. The specific aims of 
this chapter are:  
     1). To measure the degradation rate and half-life of human IL10 mRNA after transcription 
inhibition in the control group 
     2). To measure the degradation rate and half-life of human IL10 mRNA after transcription 
inhibition in the SLE group 
  3). To compare these two groups with student t-test.  
     4). To further subdivide into groups with risk and non-risk alleles of rs3122605, in order to 
analyze the influence of genetic variation around IL10 AREs on degradation rate and 
half-life.  
3. Materials and methods 
3.1 Decay assay 
3.1.1 Cell culture and Actinomycin D treatment  
Lymphoblastoid cell lines (LCL) were cultured in RPMI 1640 with 10% fetal bovine 
serum and AAA. To detect the degradation rate, each cell line was treated with Actinomycin 
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D (Act D) to block transcription and inhibit the production of fresh mRNA via binding DNA 
at the transcription initiation complex to prevent RNA elongation [82-86]. This method is a 
classical and well-established. Alternative methods to measure mRNA degradation rate 
include measurement of mRNA decay rate during uracil chase by extraction and 
biotinylation of mRNA after modified uracil chase, and indirect measurement of changes in 
mRNA level [86-91]. Modified uracil chase approach usually can be used in microarrays 
[91].   
 
3.1.2 RNA isolation 
Cell lines were at a concentration of 1x10
6
/ml in each well after 24 hours of serum 
starvation. RNA was extracted at a total of six time points: 0 hours without Act D treatment, 
and after treatment (0.5h, 1h, 2h, 3h, and 4h) [61]. RNeasy mini kit (Qiagen) was used to 
extract total RNA.  
 
3.1.3 Real time quantitative reverse transcription-PCR 
Reverse transcription PCR reactions were performed and measured on 7500 Real Time 
PCR System using SuperScript reverse transcriptase (Life Technologies) and Taqman gene 
expression master mix (Life Technologies). Total RNA was performed at 37°C for 1 h, 
followed by heat inactivation at 95°C for 5min to inactivate the enzyme. cDNA was then 
amplified by human IL10 primers and probe mentioned in chapter one on 7500 Real Time 
PCR System. Relative expression was calculated using the ΔCt method with the HPRT1 
gene (Applied Biosystem/Life Technologies) as housekeeping gene. Duplex quantitation 
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was performed in each well with VIC-dye labeled HPRT1 primers and probe and FAM-dye 
labeled IL10 primers and probe.  
 
3.1.4 Calculation of mRNA degradation rate and half-life  
Many previous studies have observed that mRNA degradation has properties of a 
one-phase exponential decay [92-95]. Thus, we analyzed human IL10 mRNA degradation 
rates in each cell line by using a one-phase exponential decay equation model: 
Y=(Y0-plateau)*exp(-κ*X)+plateau on Prism.   
Y is defined as the mRNA abundance at time X. Y0 is the mRNA abundance at time 0 
without Act D treatment. Plateau is the percentage of remaining mRNA at infinite times. Κ 
is the degradation rate constant, which we use as an estimate of the degradation rate [61]. 
Half-life can be calculated by ln(2)/K.  
  
4. Results 
We measured human IL10 mRNA half-life in 26 European American LCLs which have been 
genotyped for genetic variants associated with SLE development by using immunochips [61]. Before 
detecting, we estimated the inhibition ability of Actinomycine D (Act D), which prevents 
transcriptional progress by arresting transcription initiation complex elongation. Titration was 
performed to determine the optimal concentration of ActD (Figure 6 A). We measured total mRNA 
abundance before treatment, and in the presence of Act D or 2%FBS in 1640 medium for 4 hours. 
We tested three different concentrations of Act D (5ug/ml, 10ug/ml and 30ug/ml). After 
normalization of treatment groups to the untreated group, we found that 70% mRNA were remained 
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after 4 hours 2%FBS 1640 medium treatment. 30% mRNA abundance was left after 5ug/ml Act D 
treatment. Approximately 85% mRNA abundance was suppressed by Act D treatment at its 
concentrations of 1x10^
6 
cells/ml with 10ug/ml or 30ug/ml. Considering the potential toxicity of Act 
D to cell viability, we chose to treat our cell lines with 10ug/ml Act D.  
To better estimate the half-life of human IL10 mRNA, we tested HPRT1 mRNA expression 
before Act D treatment (time point 0), and at other four different time points after treatment 
(0.5hours, 1hours, 2hours, 3hours, and 4hours). As shown in Figure 6B, HPRT1 mRNA amount 
essentially stayed at the same level over the 4 hour time course. This suggests that we can use it as 
our housekeeping gene to normalize human IL10 mRNA expression across time points.  
Considering rs3122605 is highly associated with SLE development, we investigated the impact 
of IL10 risk (G) and non-risk allele (A) on its mRNA degradation rate [31]. We divided our cell lines 
into two groups: the homozygous non-risk allele group and the homozygous risk allele group. Two 
example decay assay plots for each group are presented in Figure 6C. Surprisingly, we observed 
faster degradation rates of IL10 mRNA in SLE than in controls. Because mRNA degradation exhibits 
characteristics of one-phase exponential decay, so we used a regression equation of this decay form 
to calculate degradation rate and half-life [61, 92]. All degradation rates and half-lives are relative to 
HPRT1 degradation rate and its half-life.    
Data in Figure 6D indicates that in 12 EBV-transformed B cell lines from SLE, IL10 mRNA in 
general has a shorter half-life than in 14 controls (half-life from controls is 1.41h, half-life from 
SLE is 0.85h, P =0.0287). Meanwhile, we found an influence of the genotype on IL10 mRNA 
degradation, even when separating into SLE group and control groups (Figure 6E and 6F). To 
explore the correlation between the degradation rate and steady-state expression level, we measured 
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IL10 mRNA expression levels in LCLs from SLE and controls after 24 hours serum starvation. We 
did not observe upregulated IL10 expression in SLE group versus control group (Figure 7). Also, we 
compared each subgroup with its matched one cross group or with other subgroups within groups. 
No significant difference has been observed (Figure 7).   
In conclusion, we observed faster human IL10 mRNA degradation rates and shorter half-life in 
LCLs from SLE when compared to controls. Though there is little or no significant influence of 
IL10 SNPs in mRNA degradation, a trend of risk alleles effect tell us that limited sample size might 
in part be taken into account. In a word, this interesting finding leads us to deeply dig this 
underlying mechanism to find out its potential contribution to the development of SLE (Seen more 
in Chapter three).  
 
5. Discussion  
 The goal of this chapter is to examine the difference between human IL10 mRNA degradation 
rates and half-life in LCLs taken from SLE versus controls. This is the first time a potential 
difference has been measured. To estimate them, we first established a reliable assay that specifically 
distinguishes human IL10 mRNA from viral IL10 without cross-reactivity (Chapter 1). Then, HPRT1 
gene (which has a slow mRNA degradation rate) was chosen as our housekeeping gene. We treated 
26 LCLs with Act D after 24 hours serum starvation, conducted the decay assay thereafter, and 
calculated the half-life of human IL10 mRNA.  
    
Half-life of human IL10 mRNA 
Many studies have demonstrated that similar half-lives have been found in genes with similar 
functions [61, 96]. For example, many long-lived genes participate in cellular structure or 
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organelle-related processes. Short-lived genes (half-life of 2h or less) often encode regulatory 
proteins such as cytokines, cell surface receptors, signal transduction regulators, transcription factors 
and others enriched in metabolic progresses [96]. Of these short-lived genes, their fast mRNA 
degradation rates are required for adjustment of their own expression levels in response to different 
cellular conditions.  
Human IL10 is a short-lived gene which exhibits different half-lives in different cell type due to 
cell-specific regulatory machinery. We investigated half-lives of human IL10 mRNA in LCLs, and 
observed shorter half-lives (the mean half-life is 0.85h) of IL10 mRNA in SLE versus a longer 
half-life (the mean half-life is 1.41h) in controls. This interesting result brings up the following 
questions: is our data consistent with previous studies? Did EBV transformation somehow influence 
the half-lives? How do we explain faster degradation rates in light of the previously observed 
elevated IL-10 expression levels in SLE?  
 
Comparison of our results with previous studies 
In general, half-life is constant over the life-time. That means half-life is not changeable under a 
stable condition until the environment and other factors have been altered [94]. Half-life of IL10 
mRNA has been studied in many studies. However, few IL10 mRNA degradation rates in B cells 
have been reported. Trong Le observed a one hour-half-life of IL10 mRNA in both adults and term 
neonates PBMCs [79]. But this study calculated half-lives using a different method. They performed 
linear regression and determined the time period required to primary quantity degrading to half of 
itself as its half-life. This approach we think is easily affected by basal input, basal expression level 
and other technical skills. Therefore, the data based on this approach is not promising. To support our 
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assessment, we made an assumption (Figure 8). Given same gene with different basal quantities of 
mRNA, half-lives have been detected using two different approaches. As we mentioned above, 
half-life is a constant value and is not supposed to be altered by different basal expression levels of 
mRNA. Interestingly, varied half-lives were obtained by using their method but one constant half-life 
was observed by using ours. Thereby, it is doubtable of one hour-half-life of IL10 mRNA in PBMCs 
in Trong’s study on the one hand. On the other hand, this assumption supports our data is relatively 
more convincing.  Moreover, Pai A et.al also reported that IL10 mRNA half-life is 2.33h (relative to 
the mean cellular mRNA decay rate) in LCLs [61]. We think the longer half-life of IL10 mRNA in 
their study may result from different normalization approach.  
 
The effect of EBV-infection 
It remains unclear about the impact of EBV infection on mRNA degradation. However, recently 
EBV alkaline exonuclease protein BGLF5 which is an early lytic-phase protein was reported that it 
can affect mRNA degradation due to its RNase activity [97]. In this study, they incubated various 
mRNA with recombinant BGLF5 proteins and observed that both cellular and viral origin were 
digested by BGLF5. But no RNase activity was observed for the control protein BGLF5 D203S [97]. 
This “shutoff” phenotype also was found in the virion host shutoff (Vhs) protein (UL41) of herpes 
simplex virus during its lytic infections [98].  Read GS et al. think that destabilization of both 
cellular mRNA and viral origin helps switch the transcription program from host to viral genes and 
facilitate the sequential expression of viral genes [98].  Besides, latent membrane protein 1 (LMP1), 
which plays an important role in immortalization of B cells, can activate the Nuclear Factor-kappa B 
(NF-κB) signaling pathway via imitating the CD40 receptor expressed on B cells [99]. In the 
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activated NF-κB signaling pathway， tristetraprolin (TTP), which is an RNA-binding protein (see 
more in chapter three) can be phosphorylated by 14-3-3 proteins, which are required for nuclear 
export of p65-IkappaBalpha complexes to induce the activation of responding genes [100]. 
Phosphorylated TTP can form a complex with 14-3-3 and release ARE-containing mRNAs in order 
to downregulate mRNA degradation [100]. Therefore, our results in LCLs might not reflect IL-10 
mRNA stability in primary B cells. 
LCLs, which are surrogate models for studies in genetic variation impacts and regulatory 
variation influences in humans, are commonly used in expression quantitative trait loci studies 
(eQTL) since they mirror the gene networks underlying genetic variations in B cells [100]. However，
EBV-transformation indeed has impacts on the expression of some genes. Yoav Gilad found that 
2252 out of 9111 genes were detected in LCLs but not in primary B cells [100]. This observation is 
not surprising since EBV-infection, which activates many immune response pathways and 
immortalizes cells, causes LCLs to be different from primary B cells in many ways. However，here 
we concentrate on the half-life difference between cell lines from SLE and controls, both of which 
were treated equally with EBV infection. Thus, the impact of EBV infection in our study is equal to 
both cases and controls. In our study, we found faster degradation rates of IL10 mRNA in LCLs from 
SLE patients. To fully explore this underlying mechanism, future studies need be focused on that in 
primary B cells from SLE and controls, and in activated B cells in response to different external 
stimulations.  
  
Relationship between degradation rate and steady-state expression 
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When it comes to the relationship between degradation rate and steady-state level, many studies 
have shown that the majority of long-lived genes have higher steady-state expression levels than 
short-lives genes [61]. However, Athma A.Pai’s group has interestingly observed that some 
short-lived genes involved in auto-regulatory feedback are highly expressed [61]. Plus, it is observed 
a positive correlation between transcription and mRNA degradation rates in these genes [61]. 
Together, these results suggest that fast mRNA degradation rates might be required for fast response 
time in complex regulatory loops. Previous studies have established that IL-10 participates in an 
autocrine loop since it acts as a growth factor for B cells [101]. Thus, IL-10 mRNA might have a fast 
degradation rate and short half-life.  
To investigate the degradation rate of IL10 mRNA, we did decay assay using transcription 
inhibitor Act D to block the transcription. However, it cannot guarantee that ActD can block all of the 
transcription. Thus, we checked the efficiency of ActD first. We find that approximately 80% 
transcription can be blocked with 20% left (Figure 6A). As mentioned above, mRNA degradation 
accompanies with transcription initiation and ongoing during entire procedure. Thus, to limit the 
influence from 20% transcription to a great extent, we did serum starvation for 24hours then 
suspended 0.5x10
6
 ~1x10
6 
cell/ml/well before treated them with ActD.  
On the one hand, this approach might provide us a relatively promising data. However, we did 
not observe increased IL10 mRNA expression in LCLs from SLE patients (Figure 8), although 
elevated IL10 mRNA and protein expression levels in PBMCs from SLE have been found in many 
studies. The first explanation is that in SLE, monocytes and B cells are the main producers of IL-10, 
as mentioned in chapter one. To date, the majority studies of IL-10 expression have concentrated on 
PBMCs rather than B cells only. Thus, it is possible that there is no significant difference of B 
 34 
 
cell-derived IL-10 between in SLE and controls, in terms of total mRNA. Another explanation might 
involve the role of serum starvation in IL10 mRNA expression. Sergej Pirkmajer et.al studied 
time-dependent changes of extracellular signal-regulated kinase 1/2 (ERK1/2), the AMP-activated 
protein kinase, and acetyl-CoA carboxylase (ACC) in primary human myotubes, rat L6 myotubes 
and human embryonic kidney (HEK) 293 cells under different serum starvation conditions 
[102]. They found that there are no uniform changes across genes or cell types, such as decreased 
ACC expression and similar phosphorylated ERK1/2 expression after serum starvation in primary 
human myotubes. Although they did not provide an explanation for this observation, it is possible 
that different degradation rates of each gene might play a role. In our study, the observed faster 
degradation rate of IL10 mRNA in SLE might contribute to decreased IL10 mRNA expression, 
which could explain why we observed no difference of IL10 total expression between in SLE and in 
controls (Figure 7). Thus, future studies should compare IL10 mRNA expression before and after 
serum starvation, then measure IL10 mRNA expression in B cells from SLE and detect its half-life.  
In conclusion, IL-10 is involved in an autocrine loop with a complex regulatory circuitry, and it 
is likely that posttranscriptional regulation plays an important role. Our study is the first to explore 
the difference of posttranscriptional regulation in SLE versus controls with respect to mRNA 
degradation rate. Although the exact contribution of faster degradation rate to the observed elevated 
steady-state expression of IL-10 in SLE remains unclear, understanding the underlying mechanism of 
mRNA degradation will be valuable.    
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Figure 6. Human IL10 mRNA degradation rate and half-life in EBV-transformed B cells from controls verse 
SLE. 
(A) Titration of Act D. We measured the inhibition ability of Act D, which is a transcription blocker, by 
normalizing transcript expressions in the presence or absence of Act D for 4 hours to basal expression. Three 
different concentrations of Act D have been examined (5ug/ml, 10ug/ml and 30ug/ml). (B) Detection of 
housekeeping gene HPRT1 degradation. The Ct values of HPRT1 gene remain constant in both SLE (black) and 
control (grey) samples. (C) Decay assays: one-phase exponential degradation analysis (SLE is shown in black, 
controls is shown in grey). 26 total cell lines have been treated with Act D, and the detected mRNA percentage 
(y-axis) is shown at five time points (x-axis). Four representative samples are shown. The left figure is a 
representative plot of cell lines from homozygous SLE non-risk haplotype carriers. The right one is for cell lines 
from homozygous SLE risk haplotype carriers. (D) Half-life of human IL10 mRNA in EBV-transformed B cells 
from controls verse SLE. (E) Contribution of SLE risk SNP haplotype to half-life of human IL10 mRNA. (F) 
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Distribution of SLE risk SNP haplotype influences on half-life of human IL10 mRNA in controls verse in SLE 
group. Student t test were analyzed and no significant difference (NS) between subgroups. The error bars are 
standard deviation. The horizontal bars are means.  
 
 
 
 
 
Figure 7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. IL10 mRNA expression level in EBV-transformed B cells from controls verse SLE 
IL10 mRNA expression over HPRT1 has been measured in EBV-transformed B cell lines from healthy controls and 
SLE. Each group has been divided into three subgroups based on genotypes cell lines carrying (rs3122605, A is 
non-risk allele, G is risk allele). Considering our cell lines are from European American ancestry, we used 
rs3122605 haplotype which are highly associated with SLE to separate groups as we show here. Student t-test has 
been performed to analyze the difference either between groups or among subgroups. Student t test were analyzed 
and no significant difference between groups or subgroups.      
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Figure 8 
 
 
 
 
Figure 8. Comparison with Trong Le’s calculation for half-life with one-phase exponential decay model  
(A)Trong Le’s approach: half-life is calculated by the time period from the basal expression level to its half 
expression. Given one gene with same degradation rate (2 copies degrade per hour), different basal expression level 
leads to different half-life. We have given first group 20 copies and the other group 20 copies as their basal 
expression level. Four timepoints were set up. At each time point, copies and its percentage of mRNA remaining 
were calculated. Thus, half-life from each group was shown above. (B) This plot of percentage of mRNA remaining 
versus time after ActD treatment is to show about one-phase exponential decay model on Prism. (C) The equation 
is Y=(Y0-plateau)*exp(-κ*X)+plateau. As we show here, half-life of one gene calculated by this model is not 
affected by basal expression level.  
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Chapter 3 Role of Tristetraprolin in IL10 mRNA degradation 
1. Introduction 
1.1 Role of posttranscriptional regulation in IL10 gene expression 
As we mentioned in chapter two, RBPs and microRNAs (miRNAs) have been 
identified as key regulators at the posttranscriptional regulation level. MiRNAs are small 
non-coding RNA molecules (20-23 nucleotides) that target unique short sequences located 
in the 3’ UTR of transcripts via matching with complementary base pairs [103]. Their 
functions include the control of transcription inhibition and mRNA degradation [104].  In 
terms of IL-10 gene expression control, overexpression of miR-21 enhanced IL-10 
production in PBMCs from SLE patients [105]. MiR-142-3p/5p directly can block IL-10 
expression and its decrease can cause CD4+ T cells and B cell overactivation in SLE [106]. 
Of note, over twenty miRNAs have been uncovered that are highly associated with the 
pathogenesis of SLE [103, 107]. However，relatively few RBPs have been studied in the 
aspects of IL10 gene expression control, and possible roles played by RBPs in the regulation 
of IL10 in a SLE context remain unexplored. Therefore, in this study we will focus our 
attention on RBPs’ contribution to the development of SLE from the perspective of their 
impact on IL10 mRNA degradation.  
   
1.1.1 RBPs 
RBPs, have extensive targets spreading through the whole transcriptome, from 5’ UTR 
to 3’ UTR. They recognize their targets by highly specific interactions between their 
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sequence and structural motifs located in double or single-stranded RNAs [108, 109]. RBPs 
form ribonucleoprotein (RNP) complexes with RNA in cells. This interaction results in 
RBPs’ influence on RNA biology, from pre-mRNA splicing and polyadenylation, RNA 
editing, modification, export, mRNA localization, mRNA degradation, to translation 
[110-113] . So far, RBPs have been analyzed and classified into different families on the 
basis of specific structural motifs (RNA-binding domains, or RBDs) they bear. Major RBD 
families include RNA recognition motif (RRM, also known as RNP domain), double 
stranded RNA-binding domain (dsRBD), K-homology (KH) domain, RGG (Arg-Gly-Gly) 
box, DEAD/DEAH box, Sm domain, cold-shock domain; Pumilio/FBF (PUF or Pum-HD) 
domain, Piwi/Argonaute/Zwille (PAZ) domain and zinc finger (ZnF) [108, 114, 115]. In a 
given RBP, one or more RNA-binding domains can be arranged in various orientations. 
RRM domains contain four-stranded anti-parallel β-sheet with two helices, which 
consist of 80-90 amino acids. This β-sheet is critical to recognize the targets and bind to 
RNAs. ZnF are the domains bearing zinc coordinated residues which are divided into three 
main types: Cys2His2 (CCHH), CCCH or CCHC. CCCH and CCHC zinc fingers can 
recognize ARE sequences and bind to them. IL10 mRNA is targeted by two RBPs: 
Tristetraprolin (TTP, also known as ZFP36, TIS11, NUP475, and G0S24) and 
ARE/poly(U)-binding/degradation factor 1 (AUF1)/hnRNP D [78, 116-118]. AUF1 is a 
member of the RRM family [67]. TTP contains tandem CCCH zinc fingers [119].  
 
       1.1.2 RBPs and mRNA degradation 
There are two different factors playing roles in mRNA degradation. In our case, AREs 
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located in mRNA targets are the cis-acting factors. ARE-binding RBPs (AUBPs) are the 
trans-acting factors. For AUBPs, their functions can either be as stabilizers or destabilizers 
depending on their motifs, them RNA, and the biological environment [109]. Common 
AUBPs include TTP, AUF1, human antigen (Hu), K-homology splicing regulatory protein, 
and butyrate-responsive factor-1. They decide the fate of mRNAs by binding to 
ARE-containing targets. For instance, the ELAV/Hu proteins such as HuB, HuC and HuD, 
which contain three RRMs, are common stabilizers in neurons. These proteins block mRNA 
degradation via binding to many ARE-containing target mRNAs in neurons [120]. AUF1 
has four isoforms (p37, p40, p42, and p45) due to alternative splicing. It can act as either a 
stabilizer or destabilizer, depending on its crosstalk with other AUBPs and extracellular 
stimulation [121, 122]. The Brewer group observed slower IL10 mRNA degradation rate 
and longer lifespan in melanoma cells than in normal melanocytes cells [78]. 
TTP usually causes target degradation by binding to AREs [123-127]. Stoecklin et al 
used a genome-wide approach, which combines microarray analysis and RNA 
immunoprecipitation, to identify the targets of TTP [118]. In their study, IL10 mRNA is a 
target of TTP, as shown by RNA immunoprecipitation, and supported by finding an 
increased IL10 mRNA degradation rate in macrophages from TTP KO mice. Thus, TTP 
plays a key role in the post-transcriptional regulation of IL10 mRNA in mice. However, its 
role in human is poorly understood. In our study, we directed our attention on the role of 
TTP in IL10 mRNA degradation and tried to address the difference of IL10 mRNA 
degradation rate in LCLs from healthy controls vs SLE patients. We hypothesize that LCLs 
from SLE expressing different level of TTP exhibit a different correlation between TTP and 
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IL-10.  
 
1.2 TTP  
TTP is encoded by the gene ZFP36 located on chromosome 19q13.2 with two exons 
and one intron. It is expressed in many tissues including lung, thymus, spleen and lymph 
nodes [128]. High TTP expression levels have been reported in myeloid cells, monocytes 
and dendritic cells (Figure 9). B cells and B lymphoblasts express relatively less TTP 
(Figure 9). Additional protein domains beyond its conserved CCCH domain are required for 
its full activity [129, 130].  
The number of TTP studies is increasing, not only because of increased attention on 
posttranscriptional regulation, but also because of the development of a TTP knockout 
mouse which has growth retardation, cachexia, arthritis, and SLE-like phenotypes such as 
inflammation and autoimmunity [123]. Recent work has demonstrated that TTP can bind to 
Not1 and form the Ccr4/Caf1/Not deadenylation complex, which plays a critical role in 
deadenylation-dependent mRNA degradation [131]. The p38-MK2 signaling pathway 
regulates this TTP-mediated, deadenylation-dependent mRNA degradation by 
phosphorylation of TTP at serines 52 and 178 and recruitment of 14-3-3 to directly bind to 
TTP to inhibit this degradation pathway [132, 133]. In addition to the p38-MK2 signaling 
pathway, Bourcier and colleagues found that the ERK signaling pathway also is involved in 
the phosphorylation of TTP [134].   
Well-established targets of TTP other than IL-10 include tumor necrosis factor-α(TNF-
α), granulocyte/macrophage colony-stimulating factor (GM-CSF), interleukin (IL)-1, IL-8 
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and others [126, 135-137]. The large range of TTP targets suggests its importance in a 
variety of contexts such as cancers characterized by dysregulation of TTP targets.  
             
1.3 Role of TTP in the pathogenesis of cancers 
Well-established works on the relationship between TTP and cancers have supported 
that TTP acts as a tumor suppressor. In Stoecklins’ study, TTP downregulated the increased 
IL-3mRNA expression in v-H-ras-dependent mast cells, thereby suppressing tumor cell 
growth and delaying the onset of tumor formation via inhibiting IL-3-autocrine 
loop-dependent proliferation [138]. The same function of TTP also has been observed in 
diverse neoplastic contexts [139]. Despite the clears ties to disease in other systems, the 
influence of TTP on the development of SLE remains unexplored.  
2. Summary  
In chapter 2, we observed faster IL10 mRNA degradation in EBV-transformed B cells in SLE 
than in controls. This interesting finding directed our attention to uncovering its underlying 
mechanism. Recent studies have shown that AREs in the IL10 3’UTR are IL10 mRNA degradation 
determinants which can be specifically recognized by the RBP TTP. However, it remains unclear 
about TTP’s expression levels in SLE patients, and its role in the control of IL-10 post-transcriptional 
regulation in a SLE context. To address these questions, we detected TTP mRNA and protein 
expression in EBV-transformed B cells from SLE and controls with European American ancestry, 
and measured the correlation between TTP mRNA and IL10 mRNA.  
 
Since there is faster degradation of IL10 mRNA in SLE from chapter 2, and TTP is known to 
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increase IL10 mRNA degradation rates, we hypothesize that SLE patients might have more TTP 
being expressed. The specific aims of this chapter are: 
 
(1) To measure and compare TTP protein expression levels in EBV-transformed B cells 
from SLE and controls by using western blot 
(2) To measure and compare TTP and IL10 mRNA expression level in EBV-transformed B 
cells from SLE and controls by using quantitative RT-PCR 
(3) To analyze the correlation between TTP mRNA and IL10 mRNA in both groups using 
the Pearson product-moment correlation coefficient 
 
3. Materials and methods 
3.1 Quantitative western Blot 
Cell lines with European ancestry were at a concentration of 1x10
6
/ml in each well after 
24 hour serum starvation in order to synchronize cells status. Whole cell extracts were 
prepared and assayed by western blotting (iBLOT Gel Transfer Stacks Nitrocellulose, mini 
from Life Technologies) as described in other studies [140]. Detection and quantitation of 
signals were performed using the imaging system Odyssey (LICOR Bioscience). COX IV 
was used as a loading control.  
    
3.2 RNA isolation 
Cell lines with European ancestry were at a concentration of 1x10
6
/ml in each well after 
24 hour serum starvation. RNeasy mini kit (Qiagen) was used to extract total RNA.  
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3.3 Real time quantitative reverse transcription-PCR 
Reverse transcription PCR reactions were performed and measured on 7500 Real Time 
PCR System (Applied Biosystem) using SuperScript reverse transcriptase (Life 
Technologies) and Taqman gene expression master mix (Life Technologies). Total RNA 
was performed at 37°C for 1 h, followed by heat inactivation at 95°C for 5min to inactivate 
the enzyme. cDNA was then amplified by human IL10 primers and the probe mentioned in 
chapter one. The relative expression was calculated using the ΔCt method with the HPRT1 
gene (Life Technologies) as housekeeping gene. Triplex quantitation was performed in each 
well with VIC-dye labeled HPRT1 primers and probe, FAM-dye labeled IL10 primers and 
probe and Cy5-dye labeled TTP primers and probe (Integrated Technologies). TTP primers 
and probe sequences: Left 5’-CATGGCCAACCGTTACACC-3’; Right 5’-GACTCAGTCC 
CTCCATGGTC-3’; Probe 5’-AGAACCTCCTGTCGCTGAGC-3’. 
 
4. Results 
In this chapter, we address the question of why the half-life of IL10 mRNA is shorter in SLE 
than in controls. We specifically concentrated on the impact that TTP’s expression level has on IL10 
mRNA degradation in SLE compared to controls. At the transcript level, we did not find a difference 
in TTP expression between the groups (Figure 10A). But TTP protein expression levels were indeed 
different based on quantitative western blot with COX IV as a loading control (Figure 10B). When 
we quantified these values, we observed a significant reduction of TTP protein expression in LCLs 
from SLE (Figure 10C). In general, TTP mostly works as a destabilizer by binding to 
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ARE-containing transcripts and changing their stability. As an exception, TTP also can prevent 
inducible nitric oxide synthase mRNA by inhibiting other destabilizers’ participations [141]. In our 
case, faster IL10 mRNA degradation rate and decreased TTP expression in SLE highly suggest that 
TTP acts as a stabilizer in the regulation of IL10 mRNA degradation. This observation and 
interpretation warrants additional follow-up in future studies, in order to fully understand the impact 
of TTP on IL10 mRNA degradation in SLE.  
On the other hand, since we did not find a difference in TTP expression at the mRNA level but at 
protein level, many factors involved in posttranscriptional regulation or translation potentially could 
contribute to its decreased protein expression in SLE. For example, TTP also contains AREs in its 
3’UTR.  Thus, its own posttranscriptional regulation in SLE might cause our observed decreased 
TTP protein expression level [130]. Or, other genetic variants might also influence TTP mRNA and 
protein expression via trans expression quantitative trait loci (eQTL) effects.  
eQTLs are used to describe the effect of genetic variants on the  expression of mRNAs [142]. 
Local eQTLs, also referred to as cis eQTLs, are located near the gened whose expression they are 
associated with. Distant eQTLs, also called trans eQTLs, have been identified far from the regulated 
genes, often on a different chromosome. To determine if trans-eQTLs from the IL10 locus might be 
acting on TTP, we divided our groups into three subgroups based on IL10 genotypes.  Strikingly, we 
found that the influence of SNP rs3122605 and its haplotype on TTP expression are significant in 
control groups but not in SLE groups, at both the transcript and protein levels (Figure 10B and 10C). 
This suggests that in the control group, but not the SLE group, IL10 potential causal genetic variants 
might have trans eQTL effects on TTP expression. This interpretation is supported by the correlation 
analysis between IL10 mRNA and TTP mRNA shown in Figure 3. In the control group, IL-10 and 
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TTP expression are highly correlated (Figure 11A).  However, the correlation between IL10 mRNA 
and TTP mRNA is weak in the SLE group (Figure 11B). We also found a significant difference 
between SLE risk allele carriers and control risk allele carriers at the protein level, but not at the 
mRNA level (Figure 10C). Multiple experiments and Pearson product-moment correlation 
coefficient analysis were performed (Figure 11C). These slopes of the best fit lines were analyzed by 
student t-test (p=0.036). The significant difference of slopes between in control group and SLE group, 
strongly support our previous findings.  
        
5. Discussion   
We conducted a study of IL10 mRNA degradation in 26 human LCLs to investigate the 
underlying mechanisms of elevated IL-10 expression in SLE at the posttranscriptional level. We 
found faster IL10 mRNA degradation rates in SLE compared to controls, as mentioned in chapter 
two. To uncover this underlying mechanism, we measured TTP mRNA and protein expression levels 
in LCLs and found a reduction of TTP protein expression in SLE. As to TTP’s function, previous 
studies have elucidated that TTP destabilizes IL10 mRNA in murine macrophages and melanoma 
models [117, 118]. On the other hand, TTP acts as a stabilizer to prevent inducible nitric oxide 
synthase mRNA from degradation in Fechir et al’s study [141]. Our observation that a strong positive 
correlation between TTP mRNA and IL10 mRNA in controls, lends support to the notion that TTP 
acts as a stabilizer in LCLs, and its reduction of its protein levels causes faster degradation rates of 
IL10 mRNA in SLE.  
In this study, one inherent limitation is the usage of LCLs as our cell model. The results and 
analyses presented here might or might not generalize to primary B cells. However，LCLs are 
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considered as the best surrogate model for eQTL studies. Indeed, Yoav Gilad et al recently 
established that for 6463 out of 10641 genes differentially expressed between LCLs and primary B 
cells, the differences between them were small (only 33 genes had a fold change greater than 1.5) 
[100]. Therefore, the trans-effect of IL10 genotypes on TTP mRNA expression we detected might be 
applied to primary B cells as well.           
Taken together, we made a drawing to well interpret the potential regulatory mechanism which 
may reveal the contribution of IL10 mRNA stability to the pathogenesis of SLE (Figure 12). Figure 
12A is to show that at mRNA level, there is a relatively strong correlation between IL10 mRNA and 
TTP mRNA in controls. Trans-effect of IL10 genotype on TTP mRNA expression has been observed 
in controls. However, this correlation becomes weak in SLE. IL10 genotype has no trans-effect on 
TTP mRNA expression. Although we still cannot explain this, this interesting finding provides a new 
sight for comprehensive understanding of trans-effect eQTL and posttranscriptional regulation. We 
would like to detect this correlation in different cell lines from other ancestries. This may help us to 
find out the reasons why increased IL-10 expression is not limited to European Americans only. At 
protein level as shown in Figure 12B, because of strong correlation and trans-effect, upregulated TTP 
protein expression has been detected in controls but not in SLE. This alteration may be due to the 
changed binding affinity of TTP to risk alleles carrying IL10 mRNA. Therefore, to better confirm 
this regulatory mechanism, similar assay should be performed in primary B cells from SLE versus 
controls to investigate IL10 mRNA stability, detect the expression level of TTP, clarify the role of 
TTP in SLE through TTP knockout by siRNA or overexpression of TTP and measure the affinity of 
TTP to IL10 mRNA carrying non-risk or risk alleles in future. Detection of other RBPs involvement 
in the development of SLE will be performed as well.  
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6. Conclusions 
In conclusion, we first established a reliable method to detect human IL10 transcripts without 
cross-reaction between the EBV-derived viral IL10 in LCLs. We then observed faster IL10 mRNA 
degradation rates in SLE.  We hypothesized that TTP, a RNA binding protein might play a role in 
IL10 mRNA degradation.  
We measured 26 human LCLs from SLE and control group all who are from European 
Americans. In controls, a strong positive correlation between TTP mRNA and IL10 mRNA was 
observed (r
2
=0.68).  Two-fold higher expression of TTP in controls was detected (p=0.02). Slower 
IL10 mRNA degradation rate has been discovered (Half-life of IL10 mRNA from controls is 1.41h, 
from SLE is 0.85h, p=0.0117). These data highly suggest that TTP works as a stabilizer on IL10 
mRNA in LCLs. Meanwhile, we found decreased TTP protein expression levels in SLE. A comprised 
correlation between TTP mRNA and IL10 mRNA was observed in SLE (p=0.1).  Given the role of 
TTP as a stabilizer in LCLs, faster degradation rate of IL10 mRNA in SLE is not surprising.  
In the end, science is endless. TTP’s precise function in LCLs and the contribution of IL-10 
mRNA degradation to the steady-state gene expression are still unclear so far. However, these 
intriguing findings in our study provide a new view of the understanding of the contribution of 
post-transcriptional regulation of IL10 mRNA to the development of SLE. This may attract more 
people to get interested in this field where people have not really investigated before. It is believed 
that posttranscriptional regulation study might help us to find the reasons why increased IL-10 
expression level in SLE has been seen in the worldwide.  
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  Figure 9 
 
Figure 9. Different expression levels of TTP transcripts in distinct tissues and cell types.  
This data is provided from BioGPS dataset library. As we see here, lung expresses highest level of TTP mRNA  
among tissues. CD33+ myeloid cells are the ones expressing highest TTP mRNA. CD19+ B cells and B  
lymphoblasts produce relatively low level of TTP mRNA.  
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Figure 10 
T
T
P
 
m
R
N
A
 
r
e
l
a
t
i
v
e
 
e
x
p
r
e
s
s
i
o
n
 
o
v
e
r
 
H
P
R
T
1
C o n tr o l S L E
0
1
2
3
4
     
T
T
P
 m
R
N
A
 r
e
la
t
iv
e
 e
x
p
r
e
s
s
io
n
 o
v
e
r
 H
P
R
T
1
AA AG G G AA AG G G
0
1
2
3
4
C o n tro l                   S L E
0 .0 0 9 7 N S
 
 
TTP     
COX IV   
        
 
      
c o n tr o l S L E
0 .0 0
0 .0 5
0 .1 0
0 .1 5
T
T
P
 
 
r
e
l
a
t
i
v
e
 
e
x
p
r
e
s
s
i
o
n
 
o
v
e
r
 
C
O
X
I
V
p = 0 .0 2
   
AA AG G G AA AG G G
0 .0 0
0 .0 5
0 .1 0
0 .1 5
T
T
P
  
r
e
la
t
iv
e
 e
x
p
r
e
s
s
io
n
 o
v
e
r
 C
O
X
IV
C o n tro l                   S L E
p = 0 .0 4
             p = 0 .0 1 5
   
           
   
 
Figure 10. Tristetraprolin (TTP) mRNA, protein expression level in EBV-transformed B cells from SLE verse 
healthy controls. (A) TTP mRNA expression. It is also separated by rs3122605 SNP haplotype. Both groups are 
European ancestry. (n=14 in controls group, n= 11 in SLE group). The expression of TTP protein by SLE and 
controls, also segregated by rs3122605 SNP haplotype (A is SLE non-risk allele, G is SLE risk allele).  (B) TTP 
protein was measured by quantitative western blot. The gels are to show the approach of quantitation of florescence 
density. COX IV is loading control. (C) Production of TTP protein in EBV-transformed B cells from SLE vs 
controls. 
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Figure 11 
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Figure 11. The correlation between TTP mRNA and IL10 mRNA in controls and SLE. 25 samples were 
analyzed by Pearson product-moment Correlation coefficient approach. The best fit line was shown in figure. The 
slope of the best fit line was calculated out. (A) In control group, IL10 mRNA expression has a positive correlation 
with TTP mRNA expression. R
2
=0.68 (B) In SLE group, the positive correlation between IL10 mRNA expression 
and TTP mRNA expression was not observed. R
2
=0.10. (C) Multiple experiments were performed. The slopes from 
multiple experiments were analyzed by student t-test. 
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Figure 12. 
 
Figure 12 Potential mechanism of posttranscriptional regulation for IL10 mRNA stability 
(A) At mRNA level, our data suggests there is a strong correlation between IL10 mRNA and TTP mRNA in 
controls. This correlation leads to a trans-effect of IL10 genotype on TTP mRNA expression. The left panel shows 
this effect by increased TTP mRNA expression along with the presence of IL10 risk alleles in controls. However, 
this trans-effect has not been observed in SLE due to weakened correlation seen in the right panel. TTP mRNAs are 
in blue, IL10 mRNAs are in black. Red triangle represents IL10 risk alleles. (B) At protein level, TTP expression is 
upregulated in controls carrying risk alleles as we expected in controls but not in SLE. Given TTP works as a 
stabilizer in LCLs, increased TTP expression may partially explain the slower degradation rate of IL10 mRNA in 
controls. On the other hand, decreased TTP production partially results in faster degradation rate in SLE. Blue 
circle represents TTP protein.       
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